skip to the content

Clinical Trials

Bipolar Disorder Study

Randomized Double-Blind Trial of  Liothyronine (T3) Augmentation to Quetiapine vs Placebo Augmentation to Quetiapine for The Treatment of Bipolar Depression

Protocol ID

08-001

Protocol Description

The purpose of this study is to examine whether the thyroid hormone, liothyronine (T3), used as an augmentation to quetiapine, may improve symptoms of depression that are associated with bipolar disorder.

Eligibility Criteria

Patients diagnosed with bipolar disorder taking  lithium or valproate or tegretol for at least 4 weeks

Primary Investigator(s)

  • Rafael Braga, MD

Contact Information

Anu Tyagi, MD
atyagi@nshs.edu

Last Update

April 2, 2010
top
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Mental Health:
top
top